The incidence of dementia rises rapidly with age. Elderly people commonly have significant medical conditions that impact on cognition and functional ability. The diagnosis of dementia requires both a decline in cognition and loss of functional ability. Assessment of dementia in medical patients requires a holistic approach that encompasses the spectrum of disease from measuring impairment of specific mental abilities to evaluating handicap in the patient’s normal social setting. Similarly, treatment can be aimed at any point in this spectrum. Recent licensing of new cholinesterase inhibitors for the treatment of Alzheimer’s disease has introduced specific problems in the treatment of medical patients with dementia. This review provides a framework for clinicians to assess and treat dementia in medical patients and describes a practical approach to the prescribing of cholinesterase inhibitors in patients with concomitant medical conditions.

Keywords:
Dementia, Cognition disorders, Cholinesterase inhibitors, Alzheimer’s disease, Geriatric assessment
1.
Piccini C, Bracco L, Amaducci L: Treatable and reversible dementias: An update. J Neurol Sci 1998;153:172–181.
2.
Kay D, Beamish P, Roth M: Old age disorders in Newcastle-upon-Tyne. Br J Psychiatry 1964;110:146–158.
3.
Kaye JA: Diagnostic challenges in dementia. Neurology 1998;51(suppl 1):S45–S52.
4.
American Psychiatric Association: The Diagnostic and Statistical Manual of Psychiatric Disorders, ed 4 (DSM-IV). Washington, APA, 1994.
5.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984;34:939–944.
6.
World Health Organization: International Statistical Classification of Diseases and Related Health Problems, rev 10 (ICD-10). Geneva, WHO, 1992, vol 1.
7.
Chamie M: What does morbidity have to do with disability? Disabil Rehabil 1995;17:323–327.
8.
World Health Organisation: International Classification of Impairments, Disabilities and Handicaps. Geneva, WHO, 1980.
9.
Cummings JL, Benson DF: Dementia: A clinical approach, ed 2. Boston, Butterworths, 1992.
10.
Ganguli M: The use of screening instruments for the detection of dementia. Neuroepidemiology 1997;16:271–280.
11.
Robinson BE: Guidelines for the inital evaluation of the patient with memory loss. Geriatrics 1997;52:30–39.
12.
Knopman DS: The inital recognition and diagnosis of dementia. Am J Med 1998;104:2S–12S.
13.
Macdonald AJD: ABC of mental health – Mental health in old age. BMJ 1997;316:413–417.
14.
Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
15.
Folstein MF: Differential diagnosis of dementia. The clinical process. Psychiatr Clin North Am 1997;20:45–57.
16.
Freidl W, Schmidt R, Stronegger WJ, Irmler A, Reinhart B, Koch M: Mini-Mental State Examination: Influence of sociodemographic, environmental and behavioural factors and vascular risk factors. J Clin Epidemiol 1996;49:73–78.
17.
Teng EL, Chui HC: The Modified Mini-Mental State (3Ms) Examination. J Clin Psychiatry 1987;48:314–318.
18.
Geldmacher DS, Whitehouse PJ Jr: Differential diagnosis of Alzheimer’s disease. Neurology 1997;48(5 suppl 6):82–89.
19.
Brun A: Frontal lobe degeneration of the non-Alzheimer type revisited. Dementia 1993;4:126–131.
20.
Office of Technology Assessment Task Force: Confronting Alzheimer’s disease and other dementias. Philadelphia, Lippincott, 1988.
21.
Hashinski V: Preventable senility: A call for action against the vascular dementias. Lancet 1992;340:645–647.
22.
Tatemichi TK, Desmond DW, Stern Y, Sano M, Mayeux R, Andrews H: Prevalence of dementia after stroke depends on diagnostic criteria. Neurology 1992;42(suppl 3):413.
23.
Clarfield AM: The reversible dementias: Do they reverse? Ann Intern Med 1988;1109:476–489.
24.
Schneider LS: New therapeutic approaches to cognitive impairment. J Clin Psychiatry 1998:59(suppl 11):8–13.
25.
Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW: Hepatotoxic effects of Tacrine administration in patients with Alzheimer’s disease. JAMA 1994;271:992–998.
26.
Rogers SL, Doody RS, Mohs RC, Friedhoff LT, the Donepezil Study Group: Donepezil improves cognition and global function in Alzheimer’s disease. Arch Intern Med 1998;158:1021–1031.
27.
Smith CD, Carney JM, Starke-Reed PE, et al: Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer’s disease: Proc Natl Acad Sci USA 1991;88:10540–10543.
28.
McBee WL, Dailey ME, Dugan E, Schumaker SA: Hormone replacement therapy and other potential treatments for dementias: Endocrinol Metab Clin North Am 1997;26:329–345.
29.
Cohen G, Spina MP: Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 1998;26:689–690.
30.
McGeer PL, McGeer EG, Rogers J, Sibley J: Anti-inflammatory drugs and Alzheimer’s disease. Lancet 1990;335:1037.
31.
McGreer PL, Schulzer M, McGreer EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease. A review of 17 epidemiologic studies. Neurology 1996;47:425–432.
32.
Finkel SI: Managing the behavioural and psychological signs and symptoms of dementia. Int Clin Psychopharmacol 1997;12(suppl 4):S25–S28.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.